isabelobrien, Author at European Medical Journal - Page 54 of 68

A joint mission for social justice

Social justice is a rising priority for all industries, but particularly for the pharmaceutical sector in the wake of COVID-19 and the social inequities it unveiled. We look at how the industry is increasingly working alongside the world’s top advertising agencies to promote growth from good in their activities.

How can medical affairs lead the way in neurology?

Neurological conditions are complex and require a high level of expertise and sensitivity, making them an juicy area for medical affairs teams. How do the challenges shape the MA role in this space and how is the landscape evolving?

Edmond Chan on improving patient outcomes

Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haematology, Janssen, discusses the MA impact on improving patient outcomes.

What's next Mr President?

As the pharmaceutical industry transitions from the Trump to the Biden era, what regulatory changes can be expected and how will a new approach to healthcare policy affect the sector?

Ensuring access to medicine for all in LMICs

Addressing global access to medicine, particularly in LMICs, poses a significant challenge. As COVID-19 vaccines are distributed, how can the pharmaceutical industry ensure they reach vulnerable populations in these countries while protecting patent rights?

The reality of caregiving in a crisis

While the pandemic has placed pressure and strain on all members of society, it has had a profound and lesser acknowledged effect on unpaid and family carers. What has been the impact of COVID-19 on those looking after loved ones and how can we better support them in the future?

Dr Jerome Kim on vaccines

Dr Jerome Kim, Director General, International Vaccine Institute, discusses pharma’s role in addressing vaccine hesitancy and refusal.

Roundtable: A new dawn for data

How is the data revolution going to impact the marketing and medical functions?

Talking to Dirk Kosche

Dirk Kosche, President, Established Markets, Astellas Pharma Europe, discusses turning innovation into value for patients.

Talking to Jennifer Cain Birkmose

Jennifer Cain Birkmose, Senior Pharmaceutical Leader in Market Access, Patient Access, and Patient Advocacy, discusses clinical trials.